OCT 31, 2016
Comprehensive Ophthalmology, Cornea/External Disease
The FDA has approved multi-dose packaging of the chronic dry eye drug Restasis (cyclosporine ophthalmic solution, 0.05%).
The same formulation used in single-use vials can now be packaged in a new dropper bottle designed with a unidirectional valve and air filter technology to prevent contamination of the preservative-free medication after opening. Restasis Multidose will cost the same as a pack of single-use vials, but with considerably less plastic packaging per dose.
Restasis was approved in 2003 to increase natural tear production in dry eye patients.